WuXi Biologics (Cayman) Inc (HKSE:02269) Share Price

Company Profile

Business description
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHN
T: +86 51085353482
https://www.wuxibiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12,575

Recommended

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	9,015.40	48.70	0.54%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,461.28	171.71	-0.38%
FTSE 100	9,136.94	0.62	0.01%
HKSE	25,176.93	347.52	-1.36%
NASDAQ	21,129.67	31.38	0.15%
Nikkei 225	40,654.70	19.85	-0.05%
NZX 50 Index	12,855.97	80.44	-0.62%
S&P 500	6,362.90	7.96	-0.12%
S&P/ASX 200	8,756.40	51.80	0.60%
SSE Composite Index	3,615.72	6.01	0.17%